Publicly listed company
Who owns Parabilis Medicines
One company in the researched set discloses a stake in Parabilis Medicines, worth $135m between them. Parabilis Medicinesis listed, and this site does not cover it in its own right, so this page is the disclosing holders' side of it only rather than a full register.
Parabilis Medicines - Profile
- Type
- public company
- Based in
- United States (Cambridge, Massachusetts)
Parabilis Medicines is a clinical stage cancer biotechnology company in Cambridge, Massachusetts, founded by Harvard chemical biologist Gregory Verdine as FogPharma and renamed in 2024. Its Helicon platform makes stabilised alpha helical peptides intended to combine the target surface coverage of an antibody with the cell permeability and tunability of a small molecule, so they can bind intracellular proteins long treated as undruggable, and it pairs that chemistry with AI and physics based design tools. The lead candidate, zolucatetide (formerly FOG-001), is a direct inhibitor of the beta catenin and TCF interaction at the centre of the Wnt signalling pathway; it has shown early activity in desmoid tumours, with Phase 3 work planned for 2027, and is also being studied in familial adenomatous polyposis and hepatocellular carcinoma. The company raised about $670 million in a June 2026 initial public offering, a record for a venture backed biotech, and trades on Nasdaq as PBLS.
Source
Parabilis Medicines files nothing with the SEC, so none of this comes from a filer record. The description was written for this site in August 2026 from BioPharma Dive: Parabilis sets a record with a $670M biotech IPO, BioSpace: Parabilis Medicines, formerly FogPharma, announces new company name and unveils AI and physics based discovery platform and BioSpace: Peptide biotech Parabilis targets up to $476M IPO. The ownership figures below come from the holders' filings instead, and are sourced row by row.
The disclosed stakes
One row per position. Where a holder reports the same company in two share classes, both rows are shown rather than summed, because the class is part of a position's identity.
Where each figure comes from
A private stake has no ownership form behind it, so the source is always the holder's own filing or disclosure. Anything modelled says so, with the arithmetic.
- Alphabet Inc., as of 30 Jun 2026 source
What this page is not
It is not a complete register. It lists the holders who happen to be inside the researched set and disclosed the stake themselves. Many other shareholders can hold Parabilis Medicines without appearing here, and nothing on this page rules them out, because this page is only the disclosing holders' side. Percentages are of Parabilis Medicines where a holder stated one, and are missing where no holder did.